$6.24
+0.13 (+2.16%)
Open$6.15
Previous Close$6.11
Day High$6.38
Day Low$6.06
52W High$5.45
52W Low$2.35
Volume—
Avg Volume137.6K
Market Cap56.45M
P/E Ratio46.80
EPS$0.09
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-31.6% upside
Current
$6.24
$6.24
Target
$4.27
$4.27
$3.74
$4.27 avg
$6.64
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 26.09M | 25.83M | 25.29M |
| Net Income | 1.24M | 1.23M | 1.32M |
| Profit Margin | 4.7% | 4.8% | 5.2% |
| EBITDA | 1.70M | 1.46M | 1.67M |
| Free Cash Flow | 1.19M | 1.13M | 847.0K |
| Rev Growth | +14.0% | +0.8% | +23.4% |
| Debt/Equity | 0.09 | 0.10 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |